Redhill Biopharma Ltd logo

Redhill Biopharma Ltd(RDHL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.28
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RDHL

11/20/2026: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.

RedHill Biopharma is a micro-cap specialty biopharmaceutical company focused on commercializing gastrointestinal products and advancing a clinical pipeline. Its core strengths lie in recently acquired U.S. commercial rights for established therapies like Rebyota and Clenpiq, backed by targeted specialty promotion. The primary investment story centers on portfolio repositioning toward recurring revenue and pipeline catalysts in oncology and infectious diseases. However, key risks include financial constraints, execution uncertainties, and intense pharmaceutical competition. The stock suits high-risk growth investors willing to monitor commercial uptake, cash burn, and clinical milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the pipeline offers potential expansion catalysts, the company's small scale and early-stage growth profile present execution uncertainties.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp episodic price movements around clinical updates, regulatory announcements, or corporate restructuring news.
Value investorWeak fitNegative net income and micro-cap valuation risks make traditional value assessment challenging.
Dividend investorWeak fitThe company does not pay dividends, reinvesting capital into operations and development.
Low-risk investorWeak fitHigh share price volatility and micro-cap biotech risks expose investors to substantial capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap biotechnology shares frequently exhibit extreme price fluctuations based on news flow and market sentiment.
Valuation riskMedium / highUncertain future earnings and limited revenue scale make valuation support heavily dependent on execution.
Competition risk (specialty pharma and microbiome competition)HighThe company competes against well-funded pharmaceutical companies with established market shares.
Business qualityMediumThe business features approved commercial assets but remains constrained by micro-cap financial limitations.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccess relies entirely on smoothly executing newly acquired commercial rights and advancing clinical trials.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.50M USD
Price to earnings Ratio -
1Y Target Price 19000
Price to earnings Ratio -
1Y Target Price 19000
Volume (30-day avg) 91.9K shares
Beta 4.87
52 Weeks Range 0.28 - 1.42
Updated Date 11/21/2026
52 Weeks Range 0.28 - 1.42
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
75.0%
Active BUY / eligible
9 / 12
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -40.57%
Avg. Invested days 9
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RDHL receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by soft unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
RDHL has soft overall fundamentals (2 stars), with soft financial health, moderate growth momentum, and soft ownership. In FY2025 versus FY2024, strong earnings growth (+94.8%) is partially offset by weak cash generation (FCF margin -3376.2%), negative revenue growth (-96.4%), weak profitability (net margin -150.0%).

Financial Health Rating

★★★★★
RDHL's financial health is soft, with the relatively strongest area being moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 2865.4% of revenue). Liquidity is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is RDHL's strongest growth driver at +94.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-96.4%, negative) and free-cash-flow growth (-3.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.6% (soft) and 47.3% of outstanding shares are publicly tradable (moderate). Insider ownership is only 0.00%, which materially reduces the ownership score.

Top 5 Institutional Investors

Yorkville Advisors Global, LP 1.37%
Gagnon Securities LLC 0.99%
Citadel Advisors Llc 0.74%
Rhumbline Advisers 0.14%
Lido Advisors, LLC 0.12%

Unit Economics (Per $1K Revenue)

★★★★★
RDHL generates approximately $1,000 of gross profit, $-27,654 of operating income, and $-33,762 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and moderate capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 94.69%

Quantitative Style Profile

★★★★★
RDHL has a Value-Oriented profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Operations (United States)Revenues generated from the U.S. promotion and sale of specialty gastrointestinal products like Rebyota and Clenpiq.The primary stream comes from selling specialized prescription drugs in the U.S. market.
Licensing and GrantsCollaborative agreements, ex-U.S. licensing partnerships, and government research grants supporting pipeline programs.Non-core funds come from research grants and partnership milestones.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 1428.57
Enterprise Value -1.21M
Price to Sales(TTM) -
Enterprise Value -1.21M
Price to Sales(TTM) -
Enterprise Value to Revenue 4.99
Enterprise Value to EBITDA 0.3
Shares Outstanding 8.89M
Shares Floating 4.20M
Shares Outstanding 8.89M
Shares Floating 4.20M
Percent Insiders -
Percent Institutions 4.62

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.